Resverlogix Corp. (TSE:RVX – Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$0.05 and traded as low as C$0.05. Resverlogix shares last traded at C$0.05, with a volume of 3,000 shares.
Resverlogix Price Performance
The company has a market cap of C$8.91 million, a price-to-earnings ratio of -2.23 and a beta of 0.71. The company’s 50-day simple moving average is C$0.05 and its 200-day simple moving average is C$0.06. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Resverlogix
- With Risk Tolerance, One Size Does Not Fit All
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Stock Sentiment Analysis: How it Works
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
